Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration

2020 ◽  
Vol 4 (3) ◽  
pp. 250-263 ◽  
Author(s):  
Pravin U. Dugel ◽  
David S. Boyer ◽  
Andrew N. Antoszyk ◽  
Nathan C. Steinle ◽  
Michael P. Varenhorst ◽  
...  
Keyword(s):  
Growth Factors ◽  
Macular Degeneration ◽  
Phase 1 ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial Growth Factors ◽  
Vascular Endothelial ◽  
Phase 1 Study ◽  
Age Related ◽  
Endothelial Growth Factors

scholarly journals Macular atrophy in neovascular age related macular degeneration

2019 ◽  
Vol 4 (1) ◽  
Keyword(s):  
Growth Factors ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial Growth Factors ◽  
Vascular Endothelial ◽  
Industrialized Countries ◽  
Macular Atrophy ◽  
Age Related ◽  
Endothelial Growth Factors

Age related macular degeneration has been the leading cause of blindness in industrialized countries. Various treatments have been developed in the last few years. The pinnacle of treatment of neovascular age related macular degenerations have been anti-vascular endothelial growth factors. This article is an opinion on macular atrophy developing in neovascular age related macular degeneration.

scholarly journals A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration

Ophthalmology ◽  
2016 ◽  
Vol 123 (1) ◽  
pp. 78-85 ◽  
Author(s):  
Glenn J. Jaffe ◽  
Dean Eliott ◽  
John A. Wells ◽  
Jonathan L. Prenner ◽  
Andras Papp ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Phase 1 ◽  
Age Related Macular Degeneration ◽  
Phase 1 Study ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document